Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing ...

Acute myeloid leukemia (AML) accounts for 30% of all leukemias ... The things that can be done to achieve this goal include: • Identification of precision-based targets on MDS and AML cells • ...

Acute myeloid leukemia is a type of cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer develops from myeloid blasts cells that would ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of d, its lead investigational allogeneic T-cell immunotherapy, acute myeloid ...